Difference between revisions of "PET Amyloid Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
(44 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
:Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
 
:Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
  
:Secretary: Julie Lisiecki
+
:RSNA Staff Support: Julie Lisiecki
 
* [http://tinyurl.com/QIBA-PET-Amyloid-Roster Roster]
 
* [http://tinyurl.com/QIBA-PET-Amyloid-Roster Roster]
  
Line 20: Line 20:
 
==PET Amyloid Meetings/Call Summaries==
 
==PET Amyloid Meetings/Call Summaries==
  
*[[Media:04_13_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL-dcm-esp.pdf|04.13.2018 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_12-10_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|December 10, 2021]]
*[[Media:03_09_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|03.09.2018 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_10-08_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|October 8, 2021]]
*[[Media:02_09_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL-dcm.pdf|02.09.2018 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_09-10_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|September 10, 2021]]
*[[Media:01_12_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL-dcm.pdf|01.12.2018 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_08-24_QIBA_Amyloid_Profile_TF_Call_Summary_FINAL.pdf|August 24, 2021 Profile TF Call Summary]]
*[[Media:10_13_2017_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|10.13.2017 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_08-13_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|August 13, 2021]]
*[[Media:09_08_2017_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|09.08.2017 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_07-09_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|July 9, 2021]]
*[[Media:08_11_2017_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|08.11.2017 QIBA PET Amyloid Biomarker Committee Call Summary]]
+
*[[Media:2021_06-11_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|June 11, 2021]]
 +
*[[Media:2021_05-14_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|May 14, 2021]]
 +
*[[Media:2021_04-09_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL-AMS.pdf|April 9, 2021]]
 +
*[[Media:2021_03-12_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|March 12, 2021]]
 +
*[[Media:2021_02-12_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|February 12, 2021]]
 +
 
 +
 
  
 
'''''[[PET Amyloid BC Call Summaries Archive]]'''''
 
'''''[[PET Amyloid BC Call Summaries Archive]]'''''
Line 59: Line 65:
 
==Presentations and Reports==
 
==Presentations and Reports==
  
*[[Media:11May2018_BCMeeting_Amyloid.pdf | 05 11 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
+
*[[Media:08Jun2018_BCMeeting_Amyloid_updated.pdf | 06 08 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 +
*[[Media:11May2018_BCMeeting_Amyloid_updated.pdf | 05 11 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:13April2018_BCMeeting_Amyloid.pdf | 04 13 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:13April2018_BCMeeting_Amyloid.pdf | 04 13 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 +
*[[Media:09March2018_BCMeeting_Amyloid.pdf | 03 09 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 +
 
*[[Media:09Feb2018_BCMeeting_Amyloid.pdf | 02 09 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:09Feb2018_BCMeeting_Amyloid.pdf | 02 09 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:12Jan2018_BCMeeting_Amyloid.pdf | 01 12 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Dr. Smith]]
 
*[[Media:12Jan2018_BCMeeting_Amyloid.pdf | 01 12 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Dr. Smith]]
Line 77: Line 86:
  
 
*[[Media:02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes.pdf|02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes - presented by Dr. Perlman]]
 
*[[Media:02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes.pdf|02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes - presented by Dr. Perlman]]
 +
 +
==QIBA Funded Projects==
 +
 +
====Round 4====
 +
*[[Media:Amyloid Profile Continued Support with Brain Phantom Development.pdf | Project (X) Amyloid Profile Continued Support with Brain Phantom Development (University of Iowa)]]
 +
 +
====Round 5====
 +
*[[Media:Analyses to Support Amyloid Imaging Profile Development.pdf | Project (A) Analyses to Support Amyloid Imaging Profile Development (ADM Diagnostics, LLC)]]
 +
 +
*[[Media:Amyloid Brain PET Test-Retest Meta-analysis.pdf | Project (E) Amyloid Brain PET Test-Retest Meta-analysis (Johns Hopkins University)]]
 +
 +
*[[Media:A PET-Metabolic Tumor Volume-DRO.pdf | Project (I) A PET-Metabolic Tumor Volume-Digital Reference Object (PET-MTV-DRO) (University of Washington)]]
 +
 +
*[[Media:A Procedure to Facilitate Greater Standardization of PET Spatial Resolution.pdf | Project (J) A Procedure to Facilitate Greater Standardization of PET Spatial Resolution (Johns Hopkins University)]]

Revision as of 18:53, 12 November 2021

Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
RSNA Staff Support: Julie Lisiecki


Project Snapshot

There is a draft Profile, and current outline of the Claim is:

  • SUVr will be the measurand
  • The claim will have two components
1) Cross-sectional: single subject scan
2) Longitudinal: following subject over time

Due to the complexity of having multiple PET Amyloid tracers, a subgroup, the Test-retest Group, has been formed including academics and industry representatives from all of the major PET Amyloid tracer vendors. This group will evaluate the published data on amyloid imaging precision, to determine what level of precision can be claimed in the Profile. The committee’s goal is to have a final draft Profile by December, 2015.

Collaborations: RSNA QIBA is now an affiliate of GAAIN (Global Alzheimer’s Association International Network)

PET Amyloid Meetings/Call Summaries


PET Amyloid BC Call Summaries Archive

PET Amyloid Profile Development

Profile Supporting Material

Working Documents

Presentations and Reports

QIBA Funded Projects

Round 4

Round 5